Guardant Health Filed for a public offering of up to 5,175,000 shares of common stock. At current prices this would raise $405 million+. Guardant trades on NASDAQ under the symbol, “GH.”
Guardant provides blood tests to aid and guide cancer treatment. They are advancing programs for recurrence detection and early cancer detection. Their Guardant360 test, “provides comprehensive genomic results from a simple blood draw in approximately seven days.” This helps oncologists move beyond the limitations of tissue biopsies to match patients with the best treatments by obbtaining clinically relevant genomic information.
Guardant has a market cap of $6.6 Billion. Its stock has seen significant increase in recent months and is up over 100% since October of 2018.